Try the Demo today!
| SEC Filing | Insider | Company | Trade Date | Transaction | Shares | Avg. Price | Total | % Holdings | Return |
|---|---|---|---|---|---|---|---|---|---|
| 03-Feb-21 5:57 PM View:  | Silver Point Capital L.P. 10% Owner | PDL BioPharma Inc. (PDLI) | 01-Feb-21 | Private Purchase | 187,061 | $2.05 | $383,475.00 | < 1% 23.78M to 23.97M | |
| 31-Dec-20 6:48 PM View: | Gryska David W Director | PDL BioPharma Inc. (PDLI) | 30-Dec-20 | Private Sale | 20,000 | $2.74 | $54,800.00 | (94%) 21.39K to 1.39K | 10% |
| 04-Jan-21 5:10 PM View: | Silver Point Capital L.P. 10% Owner | PDL BioPharma Inc. (PDLI) | 30-Dec-20 | Market Purchase | 6,325,210 | $2.50 | $15,813,000.00 | 36% 17.46M to 23.78M | (1%) |
| 29-Dec-20 4:56 PM View: | Silver Point Capital L.P. 10% Owner | PDL BioPharma Inc. (PDLI) | 29-Dec-20 | Market Purchase | 268,600 | $2.69 | $722,534.00 | 2% 17.19M to 17.46M | < 1% |
| 29-Dec-20 4:56 PM View: | Silver Point Capital L.P. 10% Owner | PDL BioPharma Inc. (PDLI) | 28-Dec-20 | Market Purchase | 235,000 | $2.70 | $634,500.00 | 1% 16.95M to 17.19M | (< 1%) |
| 29-Dec-20 4:56 PM View: | Silver Point Capital L.P. 10% Owner | PDL BioPharma Inc. (PDLI) | 24-Dec-20 | Market Purchase | 128,000 | $2.65 | $339,200.00 | < 1% 16.83M to 16.95M | 2% |
| 23-Dec-20 5:50 PM View: | Silver Point Capital L.P. 10% Owner | PDL BioPharma Inc. (PDLI) | 23-Dec-20 | Market Purchase | 485,000 | $2.60 | $1,261,000.00 | 3% 16.34M to 16.83M | 4% |
| 23-Dec-20 5:50 PM View: | Silver Point Capital L.P. 10% Owner | PDL BioPharma Inc. (PDLI) | 22-Dec-20 | Market Purchase | 850,000 | $2.59 | $2,201,500.00 | 5% 15.49M to 16.34M | 4% |
| 22-Dec-20 7:51 PM View: | McLaughlin John Peter Director | PDL BioPharma Inc. (PDLI) | 22-Dec-20 | Market Sale | 277,934 | $2.61 | $724,574.00 | (58%) 477.93K to 200.0K | (4%) |
| 23-Dec-20 5:50 PM View: | Silver Point Capital L.P. 10% Owner | PDL BioPharma Inc. (PDLI) | 21-Dec-20 | Market Purchase | 230,000 | $2.63 | $604,900.00 | 2% 15.26M to 15.49M | 3% |
| 22-Dec-20 7:51 PM View: | McLaughlin John Peter Director | PDL BioPharma Inc. (PDLI) | 21-Dec-20 | Market Sale | 50,000 | $2.62 | $131,200.00 | (9%) 527.93K to 477.93K | (3%) |
| 18-Dec-20 5:35 PM View: | Silver Point Capital L.P. 10% Owner | PDL BioPharma Inc. (PDLI) | 17-Dec-20 | Market Purchase | 398,000 | $2.61 | $1,038,780.00 | 3% 14.86M to 15.26M | 4% |
| 17-Dec-20 4:48 PM View: | Monnet Dominique President and CEO | PDL BioPharma Inc. (PDLI) | 16-Dec-20 | Market Sale | 500,000 | $2.60 | $1,300,000.00 | (40%) 1.23M to 734.92K | (4%) |
| 17-Dec-20 4:49 PM View: | Stone Christopher Lewis VP, Gen. Counsel & Secretary | PDL BioPharma Inc. (PDLI) | 16-Dec-20 | Market Sale | 200,000 | $2.56 | $512,000.00 | (33%) 605.56K to 405.56K | (6%) |
| 17-Dec-20 4:48 PM View: | Gryska David W Director | PDL BioPharma Inc. (PDLI) | 16-Dec-20 | Market Sale | 75,000 | $2.68 | $201,000.00 | (78%) 96.39K to 21.39K | (< 1%) |
| 18-Dec-20 5:35 PM View: | Silver Point Capital L.P. 10% Owner | PDL BioPharma Inc. (PDLI) | 16-Dec-20 | Market Purchase | 1,350,000 | $2.58 | $3,483,000.00 | 10% 13.51M to 14.86M | 5% |
| 15-Dec-20 7:00 PM View: | Silver Point Capital L.P. 10% Owner | PDL BioPharma Inc. (PDLI) | 15-Dec-20 | Market Purchase | 1,000,000 | $2.59 | $2,590,000.00 | 8% 12.51M to 13.51M | 4% |
| 15-Dec-20 7:00 PM View: | Silver Point Capital L.P. 10% Owner | PDL BioPharma Inc. (PDLI) | 14-Dec-20 | Market Purchase | 640,000 | $2.62 | $1,676,800.00 | 5% 11.87M to 12.51M | 3% |
| 15-Dec-20 7:00 PM View: | Silver Point Capital L.P. 10% Owner | PDL BioPharma Inc. (PDLI) | 11-Dec-20 | Market Purchase | 450,000 | $2.45 | $1,102,500.00 | 4% 11.42M to 11.87M | 10% |
| 09-Dec-20 7:46 PM View: | Gryska David W Director | PDL BioPharma Inc. (PDLI) | 05-Dec-20 | Option Exercise | 66,050 | $1.64 | $108,322.00 | 218% 30.34K to 96.39K | |
| 04-Dec-20 9:17 PM View: | Gryska David W Director | PDL BioPharma Inc. (PDLI) | 03-Dec-20 | Market Sale | 75,000 | $2.52 | $189,000.00 | (71%) 105.34K to 30.34K | (7%) |
| 04-Dec-20 9:17 PM View: | Stone Christopher Lewis VP, Gen. Counsel & Secretary | PDL BioPharma Inc. (PDLI) | 02-Dec-20 | Disposition | 11,544 | -- | -- | (2%) 617.1K to 605.56K | |
| 24-Nov-20 7:25 PM View: | Gryska David W Director | PDL BioPharma Inc. (PDLI) | 23-Nov-20 | Market Sale | 50,000 | $2.43 | $121,500.00 | (32%) 155.34K to 105.34K | (11%) |
| 24-Nov-20 7:25 PM View: | O'Farrell Elizabeth G. Director | PDL BioPharma Inc. (PDLI) | 23-Nov-20 | Market Sale | 25,826 | $2.44 | $63,015.40 | (100%) 25.83K to 0 | (11%) |
| 20-Nov-20 8:22 PM View: | Bazaar Alan Lee Director | PDL BioPharma Inc. (PDLI) | 20-Nov-20 | Market Option Sale | 33,435 | $2.42 | $81,003.00 | (76%) 43.87K to 10.44K | (12%) |
| 20-Nov-20 8:22 PM View: | Bazaar Alan Lee Director | PDL BioPharma Inc. (PDLI) | 18-Nov-20 | Option Exercise | 37,080 | $1.71 | $63,406.80 | 111% 33.44K to 70.52K | |
| 20-Nov-20 8:22 PM View: | Gryska David W Director | PDL BioPharma Inc. (PDLI) | 18-Nov-20 | Option Exercise | 60,000 | $1.64 | $98,400.00 | 63% 95.34K to 155.34K | |
| 19-Nov-20 5:33 PM View: | Gryska David W Director | PDL BioPharma Inc. (PDLI) | 18-Nov-20 | Market Sale | 50,000 | $2.39 | $119,500.00 | (34%) 145.34K to 95.34K | (13%) |
| 20-Nov-20 8:22 PM View: | O'Farrell Elizabeth G. Director | PDL BioPharma Inc. (PDLI) | 18-Nov-20 | Market Sale | 63,291 | $2.38 | $150,696.00 | (71%) 89.12K to 25.83K | (14%) |
| 20-Nov-20 8:22 PM View: | Bazaar Alan Lee Director | PDL BioPharma Inc. (PDLI) | 18-Nov-20 | Payment of Exercise | 26,642 | $2.38 | $63,408.00 | (38%) 70.52K to 43.87K | (14%) |
| 19-Nov-20 5:33 PM View: | Gryska David W Director | PDL BioPharma Inc. (PDLI) | 17-Nov-20 | Market Sale | 100,000 | $2.40 | $240,000.00 | (41%) 245.34K to 145.34K | (13%) |
| 24-Aug-20 6:06 AM View: | Hernday Natasha Director | PDL BioPharma Inc. (PDLI) | 19-Aug-20 | Grant | 25,826 | -- | -- | 52% 50.0K to 75.83K | |
| 24-Aug-20 6:05 AM View: | Gryska David W Director | PDL BioPharma Inc. (PDLI) | 19-Aug-20 | Grant | 25,826 | -- | -- | 12% 219.51K to 245.34K | |
| 24-Aug-20 6:05 AM View: | O'Farrell Elizabeth G. Director | PDL BioPharma Inc. (PDLI) | 19-Aug-20 | Grant | 25,826 | -- | -- | 41% 63.29K to 89.12K | |
| 24-Aug-20 6:06 AM View: | McLaughlin John Peter Director | PDL BioPharma Inc. (PDLI) | 19-Aug-20 | Grant | 25,826 | -- | -- | 5% 502.11K to 527.93K | |
| 24-Aug-20 6:05 AM View: | Bazaar Alan Lee Director | PDL BioPharma Inc. (PDLI) | 19-Aug-20 | Grant | 25,826 | -- | -- | 339% 7.61K to 33.44K | |
| 21-Apr-20 9:53 PM View: | Bazaar Alan Lee Director | PDL BioPharma Inc. (PDLI) | 17-Apr-20 | Grant | 7,609 | -- | -- | 100% 0 to 7.61K | |
| 07-Apr-20 8:45 AM View: | Monnet Dominique President and CEO | PDL BioPharma Inc. (PDLI) | 07-Feb-20 | Payment of Exercise | 672,505 | $3.51 | $2,360,490.00 | (35%) 1.91M to 1.23M | 25% |
| 07-Apr-20 8:46 AM View: | Imbrogno Edward VP Finance, CAO and Acting CFO | PDL BioPharma Inc. (PDLI) | 07-Feb-20 | Payment of Exercise | 82,488 | $3.51 | $289,533.00 | (26%) 314.56K to 232.08K | 25% |
| 10-Jan-20 6:37 PM View: | Imbrogno Edward VP Finance, CAO and Acting CFO | PDL BioPharma Inc. (PDLI) | 08-Jan-20 | Grant | 292,208 | -- | -- | 1307% 22.36K to 314.56K | |
| 10-Jan-20 6:36 PM View: | Jene Jill M. VP, Business Development | PDL BioPharma Inc. (PDLI) | 08-Jan-20 | Grant | 194,805 | -- | -- | 100% 0 to 194.81K | |
| 10-Jan-20 6:36 PM View: | Monnet Dominique President and CEO | PDL BioPharma Inc. (PDLI) | 08-Jan-20 | Grant | 1,233,770 | -- | -- | 183% 673.66K to 1.91M | |
| 10-Jan-20 6:36 PM View: | Stone Christopher Lewis VP, Gen. Counsel & Secretary | PDL BioPharma Inc. (PDLI) | 08-Jan-20 | Grant | 422,078 | -- | -- | 212% 198.95K to 621.03K | |
| 07-Apr-20 8:48 AM View: | Stone Christopher Lewis VP, Gen. Counsel & Secretary | PDL BioPharma Inc. (PDLI) | 16-Dec-19 | Payment of Exercise | 2,686 | $3.33 | $8,944.38 | (< 1%) 619.79K to 617.1K | 21% |
| 07-Apr-20 8:48 AM View: | Stone Christopher Lewis VP, Gen. Counsel & Secretary | PDL BioPharma Inc. (PDLI) | 12-Dec-19 | Payment of Exercise | 1,240 | $3.43 | $4,253.20 | (< 1%) 621.03K to 619.79K | 23% |
| 24-Jun-19 9:41 PM View: | Hernday Natasha Director | PDL BioPharma Inc. (PDLI) | 20-Jun-19 | Grant | 50,000 | -- | -- | 100% 0 to 50.0K | |
| 01-Apr-19 5:11 PM View: | Monnet Dominique President and CEO | PDL BioPharma Inc. (PDLI) | 28-Mar-19 | Grant | 431,317 | $3.72 | $1,604,500.00 | 194% 222.59K to 653.9K | (29%) |
| 09-Jan-19 10:26 AM View: | McLaughlin John Peter CEO | PDL BioPharma Inc. (PDLI) | 31-Dec-18 | Disposition | 123,449 | -- | -- | (20%) 625.56K to 502.11K | |
| 28-Dec-18 6:30 PM View: | Garcia Peter S Vice President, CFO | PDL BioPharma Inc. (PDLI) | 27-Dec-18 | Payment of Exercise | 3,553 | $3.02 | $10,730.10 | (2%) 228.58K to 225.03K | |
| 28-Dec-18 6:29 PM View: | Stone Christopher Lewis VP, Gen. Counsel & Secretary | PDL BioPharma Inc. (PDLI) | 27-Dec-18 | Payment of Exercise | 3,581 | $3.02 | $10,814.60 | (2%) 202.53K to 198.95K |
